Contrasting Citius Oncology (CTOR) and The Competition

Citius Oncology (NASDAQ:CTOR) is one of 847 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare Citius Oncology to related businesses based on the strength of its analyst recommendations, dividends, institutional ownership, profitability, earnings, risk and valuation.

Valuation and Earnings

This table compares Citius Oncology and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Citius Oncology	$7.11 million	N/A	-1.30
Citius Oncology Competitors	$105.26 million	-$42.92 million	-9.94

Citius Oncology’s peers have higher revenue, but lower earnings than Citius Oncology. Citius Oncology is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of recent ratings and target prices for Citius Oncology and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Oncology	1	0	0	0	1.00
Citius Oncology Competitors	9766	14998	45296	1578	2.54

As a group, “Biotechnology” companies have a potential upside of 92.38%. Given Citius Oncology’s peers stronger consensus rating and higher possible upside, analysts plainly believe Citius Oncology has less favorable growth aspects than its peers.

Risk & Volatility

Citius Oncology has a beta of 3.39, suggesting that its share price is 239% more volatile than the S&P 500. Comparatively, Citius Oncology’s peers have a beta of 0.89, suggesting that their average share price is 11% less volatile than the S&P 500.

Institutional and Insider Ownership

70.5% of Citius Oncology shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 9.8% of Citius Oncology shares are owned by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Citius Oncology and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Citius Oncology	N/A	N/A	N/A
Citius Oncology Competitors	-14,339.21%	-509.11%	-45.42%

About Citius Oncology

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.